Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

PlanetRx Plans To Fill All Express Scripts Internet Rxs In Its Own Facility

  • News

Executive Summary

PlanetRx.com's revenues from its Express Scripts partnership will rise as the online pharmacy takes over the filling of Internet prescriptions from the pharmacy benefits manager, the company indicated during a Jan. 25 conference call.

You may also be interested in...



FDA's Woodcock To Testify At Adverse Drug Events Hearing Feb. 1

FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, will testify before a Senate Health, Education, Labor & Pensions Committee hearing on adverse drug events Feb. 1.

PlanetRx.com To Receive Electronic Rx Transmissions Under AHT Contract

PlanetRx.com's prescription management agreement with Internet technology firm AHT Corporation will soon allow healthcare providers to write and transmit prescriptions electronically to the PlanetRx.com website, the online pharmacy announced in its third quarter earnings report.

Express Scripts Offers Access To Lives, Not Cash, For 20% Of PlanetRx.com

Express Scripts is acquiring 19.9% of the online pharmacy PlanetRx.com in exchange for access to the PBM's customer base and third-party contracts. Express Scripts is not using cash or stock to pay for its investment in PlanetRx.

Table

View full table

Related Content

Pink Sheet
Tags:
UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By